VAIM
VAIM Co., Ltd. is the South Korean company behind the Juvelook product family. Official product material identifies VAIM as the company, while international regulator records identify it as manufacturer of Juvelook soft-tissue injectable implants.
Company reference
Section titled “Company reference”| Field | VAIM |
|---|---|
| Core Injectable Index brand | Juvelook |
| Additional brand relationship | Lenisna in international product context |
| Material relationship | PDLLA + HA hybrid injectables |
| Country | South Korea |
| Manufacturer evidence | International regulator records identify VAIM as manufacturer |
| Commercial context | Direct product information plus regional distributors |
VAIM’s Korean product site identifies the company and current Juvelook family (Juvelook product information 🔗). An Italian Ministry of Health safety-notice record identifies VAIM Co., Ltd. as manufacturer of the Juvelook soft-tissue injectable implant (Italian Ministry of Health 🔗).
Product-role matrix
Section titled “Product-role matrix”| Product or family | Product company | Manufacturer evidence | Brand or regional identity | Distributor |
|---|---|---|---|---|
| Juvelook family | VAIM | VAIM identified as manufacturer in regulator records | Juvelook i, Skin, Juvelook, Volume, and G in the current Korean family | Market-specific |
| Lenisna | VAIM relationship reported in international company profiles | Verify exact product registration | Regional/international brand context | Market-specific |
Do not assume that Lenisna is universally identical to Juvelook Volume or that every regional name maps to the current five-product Korean family.
Current Juvelook portfolio
Section titled “Current Juvelook portfolio”VAIM’s official product page lists:
- Juvelook i — 30 mg total
- Juvelook Skin — 30 mg total
- Juvelook — 50 mg total
- Juvelook Volume — 200 mg total
- Juvelook G — 200 mg total
All are presented as PDLLA + HA products, but shared total content does not create identical particle characteristics or intended product roles.
The company page records the portfolio relationship. The Juvelook brand page retains exact PDLLA and HA quantities, particle claims, preparation evidence, and intended-use wording.
International manufacturer and registration context
Section titled “International manufacturer and registration context”A Philippine regulator record identifies VAIM as manufacturer of Juvelook and lists Korean manufacturing locations, with a local importer/distributor and a registration term from August 8, 2024 to August 8, 2029 (Philippines FDA verification record 🔗).
That record is useful for one market. It does not prove:
- the same importer elsewhere
- identical registration dates in another country
- identical product variants across markets
- universal CE or FDA status
- approval of every use discussed in company media
Product safety communications
Section titled “Product safety communications”International regulator safety notices involving Juvelook should be linked to the exact product, lot, market, and corrective action. A safety notice is part of product surveillance, not proof that every VAIM product is unsafe or that the issue applies indefinitely to all markets.
The Italian Ministry record was last updated in December 2025 and links manufacturer documentation. Preserve those dates when discussing the notice.
Selective timeline
Section titled “Selective timeline”| Date | Event | Why it changes interpretation |
|---|---|---|
| 2019 | VAIM states that Juvelook launched | Establishes the initial commercial brand timeline |
| August 8, 2024 | Philippine Juvelook registration issued in the reviewed record | Provides manufacturer and distributor traceability in one market |
| 2025 | Juvelook i and Juvelook G launched in Korea | Expands the product family beyond Juvelook and Volume |
| June 2026 | Juvelook Skin launched; VAIM described a five-product lineup | Establishes the current Korean family used by this index |
The product-family milestones come from VAIM’s official media pages (2025 product launch 🔗; 2026 Juvelook Skin launch 🔗).
Company-page boundaries
Section titled “Company-page boundaries”Do not use VAIM’s product ownership or manufacturer role to infer:
- one preparation protocol for five Juvelook presentations
- one global intended use
- identical product names by country
- clinical superiority from particle-size differences
- full reversibility because the products contain HA
Related pages
Section titled “Related pages”- Regional regulation separates Korean intended use, an EU safety record, and unresolved certificate questions.
- Juvelook contains the product-family comparison.
- PDLLA explains the hybrid material architecture.
- REGEN Biotech provides a Korean PDLLA company comparison.
- Collagen Stimulators maps the full company and brand graph.